e-ISSN: Pending
Negative / Null Result ReportOpen accessMedicine· cited by 288

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

Matthew J. Reilley; Patricia McCoon; Carl Cook; Paul D. Lyne; Razelle Kurzrock; Youngsoo Kim; Richard Woessner; Anas Younes · 2018 · Journal for ImmunoTherapy of Cancer

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

BACKGROUND: The Janus kinase (JAK) and signal transduction and activation of transcription (STAT) signaling pathway is an attractive target in multiple cancers. Activation of the JAK-STAT pathway is important in both tumorigenesis and activation of immune responses. In diffuse large B-cell lymphoma (DLBCL), the transcription factor STAT3 has been associated with aggressive disease phenotype and worse overall survival. While multiple therapies inhibit upstream signaling, there has been limited success in selectively targeting STAT3 in patients. Antisense oligonucleotides (ASOs) represent a comp

Abstract by Matthew J. Reilley; Patricia McCoon; Carl Cook; Paul D. Lyne; Razelle Kurzrock; Youngsoo Kim; Richard Woessner; Anas Younes, Journal for ImmunoTherapy of Cancer (2018) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1186/s40425-018-0436-5